CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans To Seek Immediate Regulatory Approvals
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation (NYSE:CVM) has released a video presentation detailing recent Phase 3 findings and its plans to seek immediate regulatory approvals for its immunotherapy drug Multikine. The drug has shown promising results in the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN), with a 5-year survival rate of 73% compared to 45% for those who did not receive Multikine. The company is planning regulatory submissions based on these findings.
October 24, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CEL-SCI Corporation's stock may see positive movement due to promising Phase 3 results for its drug Multikine and plans to seek regulatory approvals.
The promising Phase 3 results for CEL-SCI's drug Multikine and the company's plans to seek regulatory approvals are likely to be viewed positively by investors, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100